StreetAlpha.app
Home › Stocks › MRNA

Moderna, Inc. (MRNA)

Healthcare
$206.80
▼ −3.93%
LAST CLOSE · NOV 17

Moderna develops and sells mRNA-based medicines, mainly COVID-19 vaccines, and is developing treatments for cancer and rare diseases. It last closed at $206.80 on Nov 17, down 3.93% on the day. MRNA reports earnings on Fri, Feb 12, 2027. The average 12-month price target from 10 analysts is $150.80 (-27.1% from the last close), with a high of $305.00 and a low of $80.00. Analyst consensus is Hold, based on the latest ratings from 10 firms (2 buy, 5 hold, 3 sell). Over the past 90 days StreetAlpha recorded 171 whale options trades in MRNA, 60% of them bullish and 40% bearish. In the past 30 days there were 98 dark pool prints totaling $112.4M, the largest $15.1M.

AI Auto Pilots
Is MRNA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.5B
+13.1% vs a year ago
Net income
−$2.8B
−110.5% margin
EPS (diluted)
−$7.04
Free cash flow
−$2.0B
−78.0% margin
Valuation
Market cap
$83.7B
404.6M shares
P/E
–
No P/E while losing money
Price to sales
33.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.2B
At Sep 30
Debt
$3.0B
At Sep 30
Shareholder equity
$6.8B
Shares outstanding
404.6M
At Oct 30
CEOStéphane Bancel
Employees5,800 (2024)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.5B$18.5BFY2021FY2022: $19.3B$19.3BFY2022FY2023: $6.8B$6.8BFY2023FY2024: $3.2B$3.2BFY2024FY2025: $1.9B$1.9BFY2025

From MRNA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Feb 12
2027 · Time not announced
Consensus EPS forecast
-$2.08
$529.7M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Hold
Based on 10 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
10firms
2 Buy5 Hold3 Sell
Each firm's latest rating on MRNA in the past 90 days
Average 12-month target
$150.80
▼ 27.1% downside

Based on 10 analysts who set a price target on MRNA in the past 90 days. The average target is $150.80, with a high of $305.00 and a low of $80.00, compared with the last close of $206.80.

$25$125$225$326PAST 112 TRADING DAYS12-MONTH TARGETSHIGH $305AVG $150.80LOW $80May 22LAST CLOSE+12 MO$25$125$225$326PAST 112 DAYSTARGETSHIGH $305AVG $150.80LOW $80May 22LAST CLOSE+12 MO
Highest target$305.00
Average target$150.80
Lowest target$80.00
Latest rating changes
JP MorganTarget raised
Nov 17Sell$77 → $102
Morgan StanleyTarget raised
Nov 17Hold$95 → $200
Goldman SachsTarget raised
Nov 9Hold$137 → $195
Piper SandlerTarget raised
Nov 9Buy$230 → $305
Piper SandlerTarget raised
Oct 26Buy$77 → $230
DateFirmActionRatingPrice target
Nov 17JP MorganTarget raisedSell$77 → $102
Nov 17Morgan StanleyTarget raisedHold$95 → $200
Nov 9Goldman SachsTarget raisedHold$137 → $195
Nov 9Piper SandlerTarget raisedBuy$230 → $305
Oct 26Piper SandlerTarget raisedBuy$77 → $230
Loading…

Technical Analysis

MRNA · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock sits between its 20 and 50 day averages. It is 53% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the 50 day average at $204.39, and the nearest resistance the swing high (Sep 29) at $208.90.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 9.3%/day
Key levels
$280.8052 week high+35.8%
$228.1320 day average+10.3%
$218.08Pivot R1+5.5%
$210.98Pivot+2.0%
$208.90Swing high (Sep 29)+1.0%
$206.80Last close
$204.3950 day average−1.2%
$199.71Pivot S1−3.4%
$182.50Swing low (Oct 7)−11.8%
$145.67100 day average−29.6%
$98.09200 day average−52.6%
$22.2852 week low−89.2%
Indicators
RSI (14)44.43Middle of its rangeNeutral
MACD6.24Below its signal lineBearish
Stochastic21.1Middle of its rangeNeutral
ADX (14)31.2Trending down
Williams %R-96.2Oversold below −80, overbought above −20Oversold
CCI (20)-63.3Oversold below −100, overbought above 100Neutral
Rate of change−9.5%Change over 10 sessionsBearish
ATR (14)$19.14Typical daily range, 9.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for MRNA

What happened before

See how MRNA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow is mixed102 bullish and 69 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow MRNA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MRNA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
171
Bullish
102
60%
Bearish
69
40%
Date span
Aug 20 – Nov 17
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
98
Notional
$112.4M
Largest print
$15.1M
Loading…

FLEX Options Activity

FLEX Flow →
Notable FLEX trades
None flagged
No unusually large, long-dated positions
Single-leg prints · 30D
6
$18.5M premium · + 94 multi-leg
Latest report
Nov 17

FLEX options are customized, exchange-listed contracts used mostly by institutions. StreetAlpha scans the daily FLEX report for unusually large, long-dated positions. Multi-leg structures, such as paired calls and puts used for financing or hedging, are listed but not counted in these totals.

Loading…

MRNA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲642 buying vs 344 selling
  • ▼Held by funds -2.5 pts
  • ▲Funds holding +252
  • ▲Superinvestors: 3 added, 1 cut
  • ▼Put/call 1.15 to 2.55
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1,045793+31.8%
In funds' top 103110+210.0%
Held by funds76.9%79.4%−2.5 pts
New / increased332 / 310133 / 259+63.8%
Reduced / sold out269 / 75240 / 84+6.2%
Put/call ratio2.551.15+122.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MRNA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MRNA is in one of them and how their past MRNA trades turned out.

MRNA in the AI portfolios
Loading…

MRNA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MRNA in an article yet. Here's the latest on the wider market.

MRNA Congress Trades

All congress trades →
Trades, 12 months
19
Buys
11
58%
Sells
8
42%
People
4
Last filed Nov 10
Who traded MRNA · since 2020
Latest 5 filings of 75
$1K – $15KTraded Oct 20, 2026Filed Nov 10, 2026
$1K – $15KTraded Oct 13, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 24, 2026Filed Oct 8, 2026
$1K – $15KTraded Sep 11, 2026Filed Oct 7, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KOct 20, 2026Nov 10, 202621 d
Ro KhannaD · CABuy$1K – $15KOct 13, 2026Nov 5, 202623 d
Maria Elvira SalazarRSell$1K – $15KSep 24, 2026Oct 8, 202614 d
Ro KhannaD · CABuy$1K – $15KSep 11, 2026Oct 7, 202626 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Moderna

Moderna is a biotechnology company based in Cambridge, Massachusetts, that develops medicines built on messenger RNA, or mRNA. It has three commercial products, two COVID-19 vaccines and a vaccine against respiratory syncytial virus, which it sells through the U.S. retail channel and through long-term partnerships in the UK, Canada and Australia. The company also develops candidates for cancer, rare diseases and infectious diseases such as flu and norovirus, and it works with partners including Merck and Recordati.

Headquarters
Cambridge, MA
Founded
2010